May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Effects of Prostaglandin Analogues on the Blood–Aqueous Barrier and Central Corneal Thickness of Phakic Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Author Affiliations & Notes
  • E.S. Arcieri
    Ophthalmology, University of Campinas, Campinas, Brazil
    Ophthalmology, Federal University of Uberlândia, Uberlândia, Brazil
  • P.P. T. Pierre Filho
    Ophthalmology, University of Campinas, Campinas, Brazil
  • T.H. Wakamatsu
    Ophthalmology, University of Campinas, Campinas, Brazil
  • J.P. C. Vasconcellos
    Ophthalmology, University of Campinas, Campinas, Brazil
  • V.P. Costa
    Ophthalmology, University of Campinas, Campinas, Brazil
    Ophthalmology, University of São Paulo, São Paulo, Brazil
  • Footnotes
    Commercial Relationships  E.S. Arcieri, None; P.P.T. Pierre Filho, None; T.H. Wakamatsu, None; J.P.C. Vasconcellos, None; V.P. Costa, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2454. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E.S. Arcieri, P.P. T. Pierre Filho, T.H. Wakamatsu, J.P. C. Vasconcellos, V.P. Costa; Effects of Prostaglandin Analogues on the Blood–Aqueous Barrier and Central Corneal Thickness of Phakic Patients With Primary Open Angle Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2454.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effects of topical latanoprost, travoprost and bimatoprost on the blood–aqueous barrier and central corneal thickness (CCT) of patients with primary open–angle glaucoma (POAG) and ocular hypertension (OHT). Methods: Thirty–four phakic patients with POAG or OHT with no previous history of intraocular surgery or uveitis were enrolled in this prospective, randomized, masked–observer, cross–over study. Prior to inclusion in the study, all patients were instructed to discontinue their medications for 4 weeks. Patients were randomized to use latanoprost 0.005%, travoprost 0.004% or bimatoprost 0.03% once daily (8:00 PM) for 1 month, followed by a washout period of 4 weeks between each drug. Aqueous flare was measured with a laser flare meter (Kowa FM–500). CCT was calculated as the average of five measurements using ultrasound pachymetry. Intraocular pressure (IOP) was measured with Goldmann applanation tonometry. All measurements were performed by a masked observer at 10:00 AM. Results: There were no statistically significant differences between baseline mean IOP, mean CCT, and mean flare values among the groups. There was no statistically significant increase in mean flare values from baseline when patients instilled travoprost (P=0.30), latanoprost (P=0.05) or bimatoprost (P=0.15). Furthermore, there were no statistically significant differences between mean flare values in travoprost–, latanoprost–, and bimatoprost–treated eyes (P>0.05). All medications significantly reduced the mean IOP from baseline (P<0.0001). Travoprost reduced IOP more effectively than latanoprost (P=0.01), but no statistically significant difference was observed when compared to bimatoprost (P=0.28). A statistically significant reduction in mean CCT (0.59%) from baseline was observed when patients instilled bimatoprost (p=0.01). Latanoprost (P=0.10) and travoprost (P=0.35) did not reduce mean CCT from baseline. Conclusions:Latanoprost, travoprost, and bimatoprost had no statistically significant effect on the blood–aqueous barrier of phakic patients with POAG or OHT. Bimatoprost use may be associated with a reduction in mean CCT.

Keywords: eicosanoids • inflammation • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×